Nasdaq:COCP
Cocrystal Pharma, Inc.
A clinical-stage biopharma firm advancing a pipeline of small molecule candidates for rare diseases and oncology while operating with minimal commercial revenue.
Key Metrics
Investment Thesis
Bull Case
Investors may view COCP as an attractive early-stage opportunity given its massive retained earnings deficit that provides substantial tax shields and potential for future value accretion upon commercialization. The company's focus on rare diseases offers the potential for blockbuster orphan drug revenues with limited competition, provided it can secure sufficient funding to advance its pipeline through clinical stages.
Bear Case
The stock carries extreme risk due to zero revenue generation and a cash burn rate that rapidly depletes remaining liquidity reserves below $10M. Without imminent strategic partnerships or successful IPO financing, the company faces a high likelihood of insolvency or forced asset sales at distressed valuations before any product reaches market.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for rare diseases and oncology. The company currently operates without commercial revenue, relying entirely on strategic partnerships and future financing to fund its extensive research and development pipeline targeting unmet medical needs in specialized markets.
Analysis
Management Discussion
The company reported a net loss of $17.5M in the latest period, with operating expenses totaling $17.9M driven primarily by $12.5M in research and development costs. Cash reserves decreased from $26.4M to $9.9M as the firm burned through liquidity at a rate of $16.5M annually, leaving limited runway without immediate partnership announcements or successful equity financing.
Industry Overview
The biopharmaceutical sector for rare diseases is characterized by high regulatory hurdles but offers significant returns through orphan drug exclusivity periods and premium pricing. Companies in this space typically require decades of capital investment to navigate clinical trials, making liquidity management the single most critical factor for long-term survival.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $38.8M | $18.6M | $17.9M |
| Operating Income | $-38.8M | $-18.6M | $-17.9M |
| R&D | $12.4M | $15.2M | $12.5M |
| G&A | $5.7M | $6.0M | $5.3M |
| Stock-Based Comp | $855.0K | $801.0K | $643.0K |
| D&A | $185.0K | $189.0K | $126.0K |
| Other OpEx | $20.7M | $-2.6M | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $2.0K | $-640.0K | — |
| Pre-Tax Income | $-38.8M | $-18.6M | $-17.9M |
| Income Tax | $8.0K | $-575.0K | $-374.0K |
| Continuing Ops | $-38.8M | $-18.0M | $-17.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-38.8M | $-18.0M | $-17.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-38.8M | $-18.0M | $-17.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $40.2M | $29.1M | $11.6M |
| Cash & Equivalents | $37.2M | $26.4M | $9.9M |
| Prepaid Expenses | $2.2M | $1.8M | $430.0K |
| Other Current Assets | $716.0K | $965.0K | $1.3M |
| Long-Term Assets | $662.0K | $2.2M | $1.9M |
| PP&E (Net) | $342.0K | $271.0K | $153.0K |
| Operating Leases | $274.0K | $1.9M | $1.7M |
| Other LT Assets | $46.0K | $46.0K | $29.0K |
| Total Assets | $40.8M | $31.3M | $13.5M |
| Current Liabilities | $1.2M | $3.3M | $2.4M |
| Accounts Payable | $614.0K | $1.2M | $1.5M |
| Current Leases | $233.0K | $240.0K | $301.0K |
| Other Current Liab | $369.0K | $1.8M | $585.0K |
| Long-Term Liabilities | $57.0K | $1.6M | $1.5M |
| LT Operating Leases | $57.0K | $1.6M | $1.5M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $1.3M | $4.9M | $3.9M |
| Shareholders' Equity | $39.6M | $26.4M | $9.5M |
| Retained Earnings | $-297.9M | $-315.9M | $-333.4M |
| Total L&E | $40.8M | $31.3M | $13.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-38.8M | $-18.0M | $-17.5M |
| Non-Cash Adjustments | $16.0M | $1.7M | $2.9M |
| Working Capital Changes | $1.4M | $1.6M | $-1.9M |
| Cash from Operations | $-21.4M | $-14.7M | $-16.5M |
| Capital Expenditures | $74.0K | $118.0K | $8.0K |
| Cash from Investing | $-74.0K | $-118.0K | $-8.0K |
| Cash from Financing | $-27.0K | $4.0M | $0 |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-21.5M | $-10.8M | $-16.5M |
| Beginning Cash | $58.8M | $37.2M | $26.4M |
| Ending Cash | $37.2M | $26.4M | $9.9M |
Frequently Asked Questions
How does Cocrystal Pharma, Inc. make money?
1) Rare Disease Therapeutics (targeting orphan indications with high patient need), 2) Oncology Solutions (developing novel mechanisms for cancer treatment), 3) Strategic Licensing & Partnerships (seeking external funding through asset licensing deals), 4) Government Grants & Tax Credits (leveraging R&D tax incentives to offset losses).
What are the main risks for COCP?
1) Complete reliance on external capital raising due to lack of commercial revenue streams, 2) High probability of asset dilution through equity issuance to cover substantial cash burn rates, 3) Regulatory delays or failures in clinical trials for key drug candidates, 4) Potential loss of tax credit benefits if financial metrics change significantly.
What is COCP's competitive advantage?
1) Proprietary Small Molecule IP protecting high-value rare disease targets, 2) Experienced Management Team with deep expertise in clinical development and regulatory pathways, 3) Favorable Tax Position utilizing significant net operating loss carryforwards to shield future earnings.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.